Biotech News

HCW Biologics Reports Third Quarter 2026 Business and Clinical Development Highlights and Financial Results

HCW Biologics (HCWB)HCW BiologicsEarnings

HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on developing transformative fusion immunotherapeutics to treat autoimmune diseases, cancer and senescence-associated dysplasia, today reported financial results and recent business highlights for the three and nine months ended September 30, 2026.

Related news

HCW Biologics

Fusion Immunotherapeutics HCW Biologics is a clinical-stage biopharmaceutical company developing fusion immunotherapeutics for autoimmune disease, cancer, and conditions associated with chronic inflammation and cellular senescence. Its pipeline is built around engineered cytokine and multispecific immune-cell engagement...

Recent company news

Stock data

Close
0.74 USD
Market cap
12.82M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States